Clinical Trials Using Lirilumab
Clinical trials are research studies that involve people. The clinical trials on this list are studying Lirilumab. All trials on the list are supported by NCI.
NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.
Phase Ib Feasibility Trial of Neoadjuvant Nivolumab / Lirilumab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
Patients with muscle-invasive bladder cancer (MIBC) who can not receive cisplatin or refuse cisplatin therapy will receive nivolumab or nivolumab / lirilumab before a planned surgical procedure called a radical cystectomy (RC) to remove the bladder. Nivolumab works by attaching to and blocking a molecule called Programmed Death-1 (PD-1). Lirilumab attaches to and blocks a group of molecules called Killer Cell Immunoglobulin-Like Receptor (KIR). PD-1 and KIR are proteins present mainly on immune system cells, and each controls part of the immune system by shutting it down. It is hoped that by binding to and inactivating these proteins, these drugs can enhance the body's ability to detect, attack and destroy cancer cells. The purpose of this research study is to see whether nivolumab alone or combination of nivolumab and lirilumab given before surgery is effective in treating people who have bladder cancer, and to examine the side effects, good and bad, associated with nivolumab and lirilumab.
Location: 8 locations
Nivolumab and Lirilumab before and after Surgery in Treating Patients with Relapsed and Resectable Squamous Cell Carcinoma of the Head and Neck
This phase II trial studies how well nivolumab and lirilumab work when given before and after surgery in treating patients with squamous cell carcinoma of the head and neck that has come back (relapsed) and that can be removed by surgery (resectable). Immunotherapy with monoclonal antibodies, such as nivolumab and lirilumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving nivolumab and lirilumab after surgery may kill any remaining cancer cells in patients with squamous cell carcinoma of the head and neck.
Location: 4 locations